Table 2 Mental and physical wellbeing according to Short-Form 12-item (SF-12) questionnaire in middle-aged adults receiving placebo or synbiotic for 30 days.

From: Improvement of gastrointestinal discomfort and inflammatory status by a synbiotic in middle-aged adults: a double-blind randomized placebo-controlled trial

 

Placebo

Synbiotic

Baseline

Day 30

Baseline

Day 30

Mental Component Score (MCS)

45 ± 10.8

46.8 ± 11.3

50 ± 7.2

48.4 ± 5.8

Physical Component Score (PCS)

51.5 ± 7.9

50.6 ± 6.1

52.9 ± 5

54.1 ± 4.2

Physical function

87.5 ± 23.5

89.3 ± 18.9

94.2 ± 15

94.2 ± 11

Role physical

85.7 ± 18.9

84.8 ± 18.5

92.3 ± 10.9

95.2 ± 9.6

Bodily pain

78.6 ± 23.7

83.9 ± 23.2

90.4 ± 12.7

94.2 ± 11

General health

65.4 ± 10.6

62.9 ± 15.2

66.9 ± 13.6

68.1 ± 15.8

Vitality

33.9 ± 21

28.6 ± 25.7

46.2 ± 13.9

38.5 ± 21.9

Social function

89.3 ± 16.2

83.9 ± 23.2

90.4 ± 12.7

90.4 ± 12.7

Role emotional

75.9 ± 19.3

84.8 ± 18.5

92.3 ± 10.9

90.4 ± 11.6

Mental health

66.1 ± 23.2

66.1 ± 23.2

74 ± 15.7

73.1 ± 13.4

  1. Values are means ± SD (placebo: n = 14, synbiotic: n = 13). Matched-pairs Wilcoxon signed-rank tests were performed to compare changes from baseline (within-group variations; p > 0.05). Between-groups variations were analyzed by Mann–Whitney U-tests (p > 0.05).